Form 4 for KYMR Kymera Therapeutics, Inc.
Accepted 2026-07-02 18:30:04 ET · period of report 2026-07-01 · accession 0001193125-26-295089 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| T | 2026-07-02 18:30 | 2026-07-01 | KYMR | Goodman Noah | Chief Business Off | S - Sale | $114.29 | -3,389 | 47.2K | -7% | -$387.3K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-07-01 | S | D | 3,389 | $114.29 | 47,179.44 | D | — | — | (F1) These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person. (F2) This number includes 373 shares acquired under the Registrant's employee stock purchase plan. |